A Study of Pembrolizumab (MK-3475) in Pediatric Participants with an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Trial Identifier: 3475-051
Sponsor: MSD
Start Date: March 2015
Primary Completion Date: October 2027
Study Completion Date: October 2027
Condition: Cancer - Other; Skin Cancer; Lymphoma; Hodgkin's lymphoma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary-English

Trial Locations

Country Location
Brazil Sao Paulo, Brazil
France Paris, France
Germany Haar, Germany
Israel Hod Hasharon, Israel
Italy Rome, Italy
Korea, Republic of Seoul, Korea, Republic of, 4130
Netherlands Haarlem, Netherlands
Sweden Stockholm, Sweden
United Kingdom Hoddesdon, United Kingdom
United States, CO Aurora, CO, United States, 80045
United States, MA Boston, MA, United States, 02445
United States, NY New York, NY, United States, 10032
United States, TX Dallas, TX, United States, 75235